Puma Biotechnology (NASDAQ:PBYI) Releases Quarterly Earnings Results, Beats Estimates By $0.12 EPS
Puma Biotechnology (NASDAQ:PBYI) reported quarterly earnings of $0.21 EPS, exceeding estimates of $0.09 by $0.12. The company generated revenue of $54.48 million, surpassing the expected $51.00 million. Puma's return on equity was 53.15% with a net margin of 20.38%. The stock traded up to $5.99, with a market cap of $301.72 million. Analysts have mixed ratings, with a consensus rating of "Moderate Buy" and a price target of $7.00. Institutional investors hold 61.29% of the stock.
Puma Biotechnology (NASDAQ:PBYI - Get Free Report) issued its earnings results on Thursday. The biopharmaceutical company reported $0.21 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.09 by $0.12, FiscalAI reports. The firm had revenue of $54.48 million for the quarter, compared to the consensus estimate of $51.00 million. Puma Biotechnology had a net margin of 20.38% and a return on equity of 53.15%. Puma Biotechnology updated its FY 2025 guidance to EPS and its Q4 2025 guidance to EPS.
Get Puma Biotechnology alerts:
Puma Biotechnology Stock Performance
- 3 small-cap biotechs with potential breakthroughs in 2024
Shares of NASDAQ:PBYI traded up $1.09 during midday trading on Friday, hitting $5.99. The company had a trading volume of 2,366,087 shares, compared to its average volume of 490,998. Puma Biotechnology has a 12-month low of $2.32 and a 12-month high of $6.07. The company has a fifty day moving average of $5.02 and a two-hundred day moving average of $4.10. The company has a market cap of $301.72 million, a price-to-earnings ratio of 6.11 and a beta of 1.35. The company has a debt-to-equity ratio of 0.10, a current ratio of 1.73 and a quick ratio of 1.62.
Institutional Inflows and Outflows
A number of large investors have recently made changes to their positions in the stock. Invesco Ltd. increased its holdings in Puma Biotechnology by 88.9% in the 1st quarter. Invesco Ltd. now owns 37,631 shares of the biopharmaceutical company's stock worth $111,000 after acquiring an additional 17,707 shares in the last quarter. Royal Bank of Canada boosted its position in shares of Puma Biotechnology by 3.8% in the first quarter. Royal Bank of Canada now owns 85,999 shares of the biopharmaceutical company's stock worth $254,000 after purchasing an additional 3,117 shares during the period. AQR Capital Management LLC increased its stake in shares of Puma Biotechnology by 366.5% in the first quarter. AQR Capital Management LLC now owns 50,458 shares of the biopharmaceutical company's stock worth $149,000 after purchasing an additional 39,641 shares in the last quarter. Dynamic Technology Lab Private Ltd bought a new stake in shares of Puma Biotechnology during the 1st quarter valued at $66,000. Finally, Geode Capital Management LLC raised its position in shares of Puma Biotechnology by 1.7% during the 2nd quarter. Geode Capital Management LLC now owns 971,674 shares of the biopharmaceutical company's stock valued at $3,333,000 after purchasing an additional 16,218 shares during the period. 61.29% of the stock is owned by hedge funds and other institutional investors.
Analyst Upgrades and Downgrades
PBYI has been the subject of several research analyst reports. Wall Street Zen downgraded Puma Biotechnology from a "strong-buy" rating to a "buy" rating in a report on Saturday. Weiss Ratings downgraded shares of Puma Biotechnology from a "buy (b-)" rating to a "hold (c+)" rating in a research report on Saturday, October 25th. One research analyst has rated the stock with a Buy rating and one has given a Hold rating to the stock. Based on data from MarketBeat, Puma Biotechnology has a consensus rating of "Moderate Buy" and a consensus price target of $7.00.
Get Our Latest Stock Report on Puma Biotechnology
About Puma Biotechnology
(Get Free Report)Puma Biotechnology, Inc, a biopharmaceutical company, focuses on the development and commercialization of products to enhance cancer care in the United States and internationally. The company offers NERLYNX, an oral version of neratinib that is used to treat adult patients with early stage HER2-overexpressed/amplified breast cancer; and advanced or metastatic HER2-positive breast cancer when combined with capecitabine.
Further Reading
- Five stocks we like better than Puma Biotechnology
- How to Buy Gold Stock and Invest in Gold
- Rivian’s Chart Says Go, But Some Analysts Still Say No
- Business Services Stocks Investing
- e.l.f. Sell-Off Is a Good Time to Buy, According to Analysts
- Investing In Preferred Stock vs. Common Stock
- T-Mobile Is The Most Oversold Mega-Cap Stock—Time to Buy?
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.
Should You Invest $1,000 in Puma Biotechnology Right Now?
Before you consider Puma Biotechnology, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Puma Biotechnology wasn't on the list.
While Puma Biotechnology currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
